1 吕琳.宫颈癌早期筛查方法研究进展[J].实用肿瘤学杂志,2011,25(4):381-383. 2 吴云云,刘鹏飞.GSTP1、XRCC1基因多态性与结直肠癌个体化治疗的研究进展[J].医学综述,2014,20(18):3319-3321. 3 韩瑛,李淑敏.分子诊断技术在卵巢癌个体化诊治中应用的现状与进展[J].癌症进展,2015,13(1):14-18. 4 Jiang J,Liang X,Zhou X,et al.ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer:a meta-analysis[J].Mol Biol Rep,2012,39(6):6933-6942. 5 Wu J,Lu LY,Yu X.The role of BRCA1 in DNA damage response[J].Protein Cell,2010,1(2):117-123. 6 付婷,秦立强,潘旭东,等.XRCC1基因多态性与晚期非小细胞肺癌铂类化疗敏感性关系的Meta分析[J].江苏医药,2015,41(12):1401-1403. 7 陈健,何义富,胡冰.核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展[J].现代肿瘤医学,2009,17(4):763-766. 8 车彪,邵增务,杨述华.Stathmin基因表达与肿瘤的研究进展[J].现代肿瘤医学,2008,16(10):1814-1817. 9 Hsieh SY,Huang SF,Yu MC,et al.Stathmin1 overexpression associated with polyploidy,tumor-cell invasion,early recurrence,and poor prognosis in human hepatoma[J].Mol Carcinog,2010,49(5):476-487. 10 Jakobsen A,Nielsen JN,Gyldenkerne N,et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity[J].J Clin Oncol,2005,23(7):1365-1369. 11 Ogura K.Dihydropyrimidine dehydrogenase activity and its genetic aberrations[J].Gan To Kagaku Ryoho,2006,33(8):1041-1048. 12 蔡乐,朱珠.二氢嘧啶脱氢酶及其与5-氟尿嘧啶疗效和毒性的关系[J].中国药学杂志,2007,42(19):1441-1445. 13 Vena F,Li CE,Rodriguez-Justo M,et al.The MEK1/2 inhibitor pimasertib enhances gemcitabine efficacy in pancreatic cancer models by altering ribonucleotide reductase subunit-1(RRM1)[J].Clin Cancer Res,2015,21(24):5563-5577. 14 Ulker M,Duman BB,Sahin B,et al.ERCC1 and RRM1 as a predictive parameter for non-small cell lung,ovarian or pancreas cancer treated with cisplatin and/or gemcitabine[J].Contemp Oncol(Pozn),2015,19(3):207-213. 15 张艳,赵军,凯塞尔·吾甫尔,等.新疆维吾尔族和哈萨克族健康人群CYP2C9和VKORC1基因多态性研究[J].中国药师,2013,16(12):1759-1763. |